Scarica l'app Stockscreener
20.66
2.38%
0.48
Dopo l'orario di chiusura:
20.66
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNDM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$20.18
Aprire:
$20.35
Volume 24 ore:
1.10M
Relative Volume:
0.69
Capitalizzazione di mercato:
$1.38B
Reddito:
$796.00M
Utile/perdita netta:
$-136.49M
Rapporto P/E:
-9.8852
EPS:
-2.09
Flusso di cassa netto:
$-64.24M
1 W Prestazione:
-2.91%
1M Prestazione:
-2.96%
6M Prestazione:
-31.75%
1 anno Prestazione:
-60.30%
Intervallo 1D:
$20.20
$20.83
Intervallo di 1 settimana:
$19.52
$21.55
Portata 52W:
$15.75
$53.63
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Nome
Tandem Diabetes Care Inc
Settore
Industria
Telefono
858-366-6900
Indirizzo
12400 HIGH BLUFF DRIVE, San Diego, CA
Confronta TNDM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
20.66 | 1.42B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
133.94 | 231.14B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.83 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.10 | 146.12B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.00 | 105.64B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.77 | 45.60B | 5.54B | 4.18B | 623.10M | 7.00 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Mizuho | Neutral |
| 2025-03-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-10-04 | Iniziato | Goldman | Neutral |
| 2024-10-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Aggiornamento | Stifel | Hold → Buy |
| 2023-08-04 | Downgrade | Citigroup | Buy → Neutral |
| 2023-05-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-15 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-08-09 | Downgrade | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Underweight |
| 2020-12-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Iniziato | Wells Fargo | Overweight |
| 2020-07-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-18 | Reiterato | Raymond James | Outperform |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-06 | Iniziato | Raymond James | Outperform |
| 2020-02-04 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Iniziato | Guggenheim | Buy |
| 2019-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2019-05-17 | Reiterato | BofA/Merrill | Neutral |
| 2019-05-13 | Iniziato | SVB Leerink | Outperform |
| 2019-03-08 | Iniziato | BMO Capital Markets | Outperform |
| 2019-03-05 | Reiterato | BofA/Merrill | Neutral |
| 2019-02-27 | Reiterato | Lake Street | Buy |
| 2018-11-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Reiterato | Dougherty & Company | Buy |
| 2018-09-26 | Reiterato | Piper Jaffray | Overweight |
Mostra tutto
Tandem Diabetes Care Inc Borsa (TNDM) Ultime notizie
Tandem Diabetes Care: A Barbell Bet On A High-Stakes Turnaround (NASDAQ:TNDM) - Seeking Alpha
(TNDM) Long Term Investment Analysis - news.stocktradersdaily.com
Tandem Diabetes at Jefferies: Expanding Market Horizons By Investing.com - Investing.com Canada
How the Non-Invasive Drug Delivery Device Market Will Evolve - openPR.com
Do You Believe in the Long-Term Growth Potential of Tandem Diabetes Care (TNDM)? - Insider Monkey
Roche settles UPC dispute over insulin distribution technology - JUVE Patent
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Benzinga
Tandem Diabetes Care Inc (TNDM) Shares Gap Down to $20.62 on May 30 - GuruFocus
Tandem Diabetes Care (TNDM) Up 6.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Contrasting Tandem Diabetes Care (NASDAQ:TNDM) and PolyPid (NASDAQ:PYPD) - Defense World
Cetera Investment Advisers Acquires 981 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Reflecting On Healthcare Technology Stocks’ Q1 Earnings: Tandem Diabetes (NASDAQ:TNDM) - Yahoo Finance
Tandem Diabetes and Roche Reach a Patent Settlement - MSN
Tandem Diabetes Care’s SWOT analysis: stock faces growth hurdles amid market shifts - Investing.com Nigeria
How the (TNDM) price action is used to our Advantage - news.stocktradersdaily.com
Tandem to pay Roche $36M in patent dispute settlement - MSN
Tandem Diabetes, Roche enter patent settlement agreement - Yahoo Finance
Tandem Diabetes Care (TNDM) Settles Patent Dispute with Roche - GuruFocus
Should Tandem Diabetes Stock Stay in Your Portfolio Now? - MSN
Tandem Diabetes To Pay Roche $36 Mln To Settle Patent Infringement Claim - Nasdaq
Tandem Diabetes Agrees to Pay Roche $36 Million in Patent Infringement Deal - marketscreener.com
Tandem Diabetes Care Settles Patent Disputes with Roche - TipRanks
Tandem Diabetes Care IncEnters Settlement Agreement With Roche EntitiesSEC Filing - marketscreener.com
Infusion Pumps Market to Hit USD 15.6 Billion by 2031, Driven - openPR.com
Deutsche Bank AG Purchases 19,308 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Bank of America Corp DE Sells 127,904 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Tandem Diabetes (TNDM) Price Target Raised by Citi, Neutral Rati - GuruFocus
Where Tandem Diabetes Care Stands With Analysts - Benzinga
Citigroup Maintains Neutral Rating on Tandem Diabetes Care (TNDM) | TNDM Stock News - GuruFocus
Tandem Diabetes Care Inc (TNDM) Trading Down 4.29% on May 21 - GuruFocus
Tandem Diabetes (TNDM) Price Target Raised by Citi, Neutral Rating Maintained | TNDM Stock News - GuruFocus
BNP Paribas Financial Markets Reduces Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Global Insulin Pumps Market Report 2021-2030: Insulet, - openPR.com
Global Insulin Pumps Market Report 2021-2030: Insulet, Medtronic, and Tandem Diabetes Care are the Major Stakeholders – Focus Report Store - Barchart.com
Fortune Brands, Whirlpool, Align Technology, Tandem Diabetes, and STAAR Surgical Shares Plummet, What You Need To Know - Yahoo Finance
Tandem Diabetes Care Inc (TNDM) Trading 3.52% Higher on May 20 - GuruFocus
Tandem Diabetes at RBC Conference: Growth and Strategic Expansion By Investing.com - Investing.com Canada
Ameriprise Financial Inc. Sells 525,159 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Investor Network: Tandem Diabetes Care, Inc. to Host Earnings Call - ACCESS Newswire
Shareholders May Be More Conservative With Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) CEO Compensation For Now - simplywall.st
Insulin Pump Market Growth, Trends & Forecast 2025 | Leading key - openPR.com
TNDM Q1 Earnings Call: Product Expansion and Channel Initiatives Drive Growth Against Margin Pressures - Yahoo Finance
Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set - MassDevice
Tandem Diabetes Care gets FDA clearance for new set By Investing.com - Investing.com India
Tandem Diabetes Earnings: Despite Solid First-Quarter Results, We Expect Growth to Decelerate - Morningstar
Tandem Diabetes Care gets FDA clearance for new set - Investing.com
Tandem's Initial Growth Spurt From the Launch of Mobi Should Moderate in the Near Term - Morningstar
INVESTOR ALERT: Levi & Korsinsky Notifies Tandem Diabetes Care, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – TNDM - ACCESS Newswire
Tandem Diabetes Care Inc Azioni (TNDM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):